Recruiting

Miricell

Sponsor:

Nutraland USA, Inc.

Code:

NCT07675200

Conditions

Autophagy

Healthy Aging

Eligibility Criteria

Sex: All

Age: 40 - 70

Healthy Volunteers: Accepted

Interventions

Spermidine

Placebo

Study Details

Brief summary:

The goal of this clinical trial is to learn if a dietary supplement called Miricell works to improve cellular health and signs of healthy aging in adults. It will also learn about the safety of Miricell.

The main questions it aims to answer are:

  • Does Miricell improve markers of autophagy, which is the body's natural process for recycling damaged cells?
  • Does Miricell support brain health, metabolic health, and visible signs of aging?
  • What medical problems, if any, do participants experience while taking Miricell?

Researchers will compare Miricell to a placebo (a look-alike capsule that contains no active ingredients) to see if Miricell works better to support healthy aging.

Participants will:

  • Take either one Miricell capsule or a placebo every day for 12 weeks with a morning meal.
  • Visit the research clinic four times over the course of the study for checkups and tests.
  • Complete memory and thinking tests, track their daily physical activity, and give blood samples to measure health changes.

Conditions

Autophagy

Healthy Aging

Study ID

NCT07675200

Start date

Jan 9, 2026

Status verified date

Jun, 2026

Completion date

Sep, 2026

Anticipated

Primary completion date

Sep, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 40 - 70

Healthy Volunteers: Accepted

INCLUSION CRITERIA:

  • Provide voluntary signed and dated informed consent.
  • Be in fair health as determined by medical history and routine blood chemistries.
  • Age between the ages of 40 and 70 (inclusive).
  • Body weight of at least 110 pounds.
  • Normotensive (seated, resting systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg. If the first measurement is slightly elevated above these limits, the subject will be given a brief (5-minute) rest period, and two more measurements will be taken. The average of all three measurements will be used to determine eligibility.
  • Normal seated, resting heart rate (<90 per minute).
  • Willing to duplicate their previous 24-hour diet, refrain from alcohol for 24 hours, exercise for 24 hours prior to each trial, caffeine for 12 hours prior to each trial, and fast for 10 hours prior to each of the treatments.
  • Participant agrees to maintain existing dietary and physical activity patterns throughout the study period.
  • Participant is willing and able to comply with the study protocol.
  • If a dietary supplement was initiated within the past month, the participant is willing to discontinue supplement use followed by a 2-week washout prior to participation in the study.
  • Able to provide an adequate blood draw.

EXCLUSION CRITERIA:

  • Use of probiotics, postbiotics or antibiotics within the past month.
  • A history of unstable or new-onset cardiovascular/cardiorespiratory, liver, or renal disease.
  • The participant's alcohol consumption is more than two standard alcoholic drinks per day or more than 10 drinks per week or has a history of drug/alcohol abuse or dependence.
  • History of diabetes (any form) or any endocrine disorder.
  • Fasting blood sugar of > 125 mg/dL.
  • Current smokers who smoke 11 or more cigarettes per day (i.e. light smokers will be enrolled if they meet all other criteria).
  • History of hyperparathyroidism or an untreated thyroid disease.
  • History of malignancy in the previous five years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
  • Chronic inflammatory condition or disease (e.g., rheumatoid arthritis, Crohn's Disease, ulcerative colitis, lupus, HIV/AIDS, etc.).
  • Previous medical diagnosis of gout or fibromyalgia.
  • Any female who is pregnant, trying to become pregnant, is less than/or equal to 120 days postpartum, or any current women who are nursing.
  • Women who participate in this study must agree to the use of contraception for the duration of the study, and any sexually active woman will have to take a negative pregnancy test prior to enrolling. Women of childbearing age (any woman prior to menopause), regardless of their use of contraception, will be provided a urine pregnancy test kit at their screening visit and take the test in private using the female lavatory after signing an informed consent.
  • Known allergy or sensitivity to any ingredient in the test formulations as listed on the product label.
  • Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.

Study Design

Enrollment

70 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

active comparator: Miricell™

Participants assigned to this arm will receive one capsule of the active branded spermidine supplement (Miricell) daily for a total duration of 12 weeks.

placebo comparator: Placebo

Participants assigned to this arm will receive one look-alike placebo capsule daily for a total duration of 12 weeks.

Interventions

Spermidine

Branded spermidine ingredient (Miricell® Rice Germ Extract) administered orally at a dose of 3.3 mg/day. Provided as a single opaque capsule to be ingested daily with water in the morning with a meal.

Placebo

Placebo capsule (microcrystalline cellulose) packaged in an identical-looking, opaque capsule to be ingested daily with water in the morning with a meal.

Primary outcome measure

  • Serum Beclin-1 Concentration [ Time Frame: Baseline (Week 0), Week 6, and Week 12 ]
  • Serum ULK1 Concentration [ Time Frame: Baseline (Week 0), Week 6, and Week 12 ]

Central Contacts and Locations

Central contacts

Michael B La Monica, Ph.D., CSCS

330-206-0767ML@appliedhealthsciences.org

Locations

The Center for Applied Health Sciences

Recruiting

Canfield, Ohio, United States, 44406

Contacts

Michael B La Monica, Ph.D., CSCS

330-206-0767ML@appliedhealthsciences.org

More Information

Sponsor

Nutraland USA, Inc.

Last update posted

Jun 30, 2026

Last verified

Jun, 2026

Keywords

  • Spermidine
  • Polyamines
  • Cognitive Function
  • Miricell(R)
  • Cellular Health

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Nutraland USA, Inc. on 2026-06-30.